

Supplementary Table 1. Patients' clinical data.

	Age	Gender	Race	Smoking status	Stage	Differentiation	Survival Status	N stage	T stage	M stage	EGFR mutation	Treatment
Patient 1	69	F	W	Former smoker 10pkyear quit 1970	IV	Well-differentiated	Deceased	N2	T4	M1a	L858R	Erlotinib Initiated 06/13 Osimertinib 4/16 for T790M
Patient 2	76	F	W	Never smoker	IV	NA	Alive	N3	T3	M1a	L858R	Erlotinib 12/14 Osimertinib 06/16 T790M
Patient 3	59	F	AA	Former smoker 13pkyear quit 1985	IV	NA	Deceased	N3	T3	M1a	Del19	Erlotinib 05/14 Progressed 04/15
Patient 4	75	F	W	Never smoker	IV	NA	Deceased	N2	T2	M1b	Del19	09/17 Untreated
Patient 5	76	M	W	Former smoker 165pkyear quit 2012	IV	NA	Alive	N2	T3	M1b	Del19	08/17 Diagnosed 03/18 Osimertinib
Patient 6	58	M	W	Never smoker	IV	Mod differentiated	Alive	N2	T2	M1b	Insertion 20	09/17 Diagnosed
Patient 7	54	F	W	Former smoker 3pkyear quit 1998	IV	Poor differentiated	Alive	N2	T2	M1a	L858R	02/14 Erlotinib 04/14 Afatinib 6/16 Tagrisso
Patient 8	72	M	W	Never smoker	IV	NA	Deceased	Nx	T2	M1b	L858R	03/14 Erlotinib 09/15 Afatinib 12/15 Osimertinib
Patient 9	60	F	W	Former smoker 1.3pkyear quit 2000	IV	Mod differentiated	Alive	N2	T2	M1a	Del19	10/13 Erlotinib 11/15 Osimertinib
Patient 10		F	W	Never smoker	IV	NA	Alive	N2	T2	M1a	Del19	11/13 Afatinib 01/16 Osimertinib